MilliporeSigma, the life science business of Germany-based Merck KGaA, reports that it is investing €35 million ($37 million) in biosafety testing at its Glasgow and Stirling sites in Scotland. The expansion is expected to create nearly 500 new jobs, bringing the company’s workforce to over 1,200 employees across the two sites.
“We remain committed to ensuring the safety of the world’s medicines through our state-of-the-art testing solutions for our customers around the world that drive new treatments,” said Dirk Lange, head of life science services, MilliporeSigma. “Since mid-2022, we have announced investments of more than €350 million [$373 million] in our global testing network to meet the growing demand for these services.”
“The biosafety testing services at our sites in Glasgow and Stirling have been experiencing strong, double-digit growth for several years,” pointed out David McClelland, site head and managing director for the Scottish sites. “This investment is a significant announcement for us in Scotland and an acknowledgment of the great work of our on-site teams.”
With its BioReliance® testing services portfolio, Merck KGaA performs more than 20,000 studies in the U.K. annually for more than 500 clients globally, noted McClelland.
“BioReliance contract testing services and the recently formed Millipore® CTDMO services are part of the life science services business unit, which together with the process solutions business is one of the ‘Big 3’ growth drivers of Merck KGaA,” he added.